Loading...
•
Dec 31, 2023
Pacira Q4 2023 Earnings Report
Pacira BioSciences reported financial results, with fourth quarter revenues of $181.2 million and GAAP net income of $24.9 million.
Key Takeaways
Pacira BioSciences reported Q4 2023 financial results, featuring a 5% increase in total revenues to $181.2 million and a GAAP net income of $24.9 million, or $0.54 per basic share. The company also reported an adjusted EBITDA of $65.4 million for the quarter.
Total revenues increased by 5% to $181.2 million compared to Q4 2022.
EXPAREL net product sales increased by 4% to $143.9 million compared to Q4 2022.
GAAP net income was $24.9 million, or $0.54 per basic share and $0.50 per diluted share.
Adjusted EBITDA increased by 11% to $65.4 million compared to Q4 2022.
Revenue by Segment
Forward Guidance
The company is providing full-year 2024 financial guidance as follows: Total revenue of $680 million to $705 million; Non-GAAP gross margin of 74% to 76%; Non-GAAP R&D expense of $70 million to $80 million; Non-GAAP SG&A expense of $245 million to $265 million; and Stock-based compensation of $50 million to $55 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...